$2.4 Billion Dollar man joins Trevali as ChairmanWith ID Biomedical he was directly responsible for returning 1.7 Billion Dollars to shareholders by selling his company to GlaxoSmithKline. He was partially responsible as chairman of Corriente in returning 700 million dollars to shareholders. Trading on the TSX with Glencore as a partner and Dr. Anthony Holler as chairman Trevali is setup as being the next rising star in the Cardero group of companies.
"I am very pleased to be joining the board of Trevali as its Chairman," said Dr. Holler. "Based on my experience with similar business situations, I would say that Trevali represents a tremendous opportunity to create significant shareholder value. As Chairman of Corriente Resources, we developed a plan to enhance the value of the company by advancing our copper/gold property through bankable feasibility. We were able to build significant shareholder value, and ultimately decided to capitalize on this value by selling the company for about $700 million. Similarly, at ID Biomedical where I was CEO, we created value by moving our products from R&D through the development and commercialization phases. Again, we decided to capitalize on the value of the assets we developed by selling the company to GlaxoSmithKline for approximately $1.7 billion. I believe that my experience can be beneficial to Trevali at its current stage of development. This Company has all the ingredients for success; an experienced management team, a valuable silver/zinc asset and a senior partner in Glencore who will operate the mine. I look forward to assisting management in developing Trevali's attractive assets and maximizing shareholder value."